AC Immune (ACIU) Common Equity (2014 - 2026)

AC Immune (ACIU) has 13 years of Common Equity data on file, last reported at $40.3 billion in Q1 2026.

• On a quarterly basis, Common Equity rose 38091.77% year-over-year to $40.3 billion in Q1 2026; TTM through Mar 2026 was $40.3 billion, a 38091.77% increase from a year earlier, with the FY2025 full-year figure at $54.1 billion, up 42141.29% from the prior year.
• Common Equity for Q1 2026 stood at $40.3 billion, down from $56.2 billion in the prior quarter.
• Over the last five years, Common Equity for ACIU reached as high as $231.9 billion in Q1 2022 and fell as low as $78.1 million in Q3 2025.
• Historically, Common Equity has averaged $31.8 billion across 5 years, with a median of $165.3 million in 2023.
• Across the five-year window, Common Equity tumbled 99.93% in 2023 and jumped 43718.74% in 2025, its largest moves.
• Year by year, Common Equity stood at $175.4 million in 2022, then advanced by 3.24% to $181.1 million in 2023, then decreased by 29.23% to $128.2 million in 2024, then soared by 43718.74% to $56.2 billion in 2025, then fell by 28.29% to $40.3 billion in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $40.3 billion in Q1 2026, $56.2 billion in Q4 2025, and $78.1 million in Q3 2025.